IBRX Q3 2022 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118,000+78.8% YoY

Gross Profit

-$6M-4963.6% margin

Operating Income

-$91M-76952.5% margin

Net Income

-$111M-94015.3% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+237.1%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$97M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$353M

Total Liabilities

$782M

Stockholders' Equity

-$427M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118,000	$66,000	+78.8%
Gross Profit	-$6M	$66,000	-8974.2%
Operating Income	-$91M	-$79M	-15.2%
Net Income	-$111M	-$88M	-26.6%